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Abstract
Background: Quantitative electroencephalogram (EEG) is one neuroimaging technique that has been shown to
differentiate patients with major depressive disorder (MDD) and non-depressed healthy volunteers (HV) at the
group-level, but its diagnostic potential for detecting differences at the individual level has yet to be realized.
Quantitative EEGs produce complex data sets derived from digitally analyzed electrical activity at different frequency
bands, at multiple electrode locations, and under different vigilance (eyes open vs. closed) states, resulting in
potential feature patterns which may be diagnostically useful, but detectable only with advanced mathematical
models.
Methods: This paper uses a data mining methodology for classifying EEGs of 53 MDD patients and 43 HVs. This
included: (a) pre-processing the data, including cleaning and normalization, applying Linear Discriminant Analysis
(LDA) to map the features into a new feature space; and applying Genetic Algorithm (GA) to identify the most
significant features; (b) building predictive models using the Decision Tree (DT) algorithm to discover rules and
hidden patterns based on the reduced and mapped features; and (c) evaluating the models based on the accuracy
and false positive values on the EEG data of MDD and HV participants. Two categories of experiments were
performed. The first experiment analyzed each frequency band individually, while the second experiment analyzed
the bands together.
Results: Application of LDA and GA markedly reduced the total number of utilized features by ≥ 50 % and, with all
frequency bands analyzed together, the model showed average classification accuracy (MDD vs. HV) of 80 %. The
best results from model testing with additional test EEG recordings from 9 MDD patients and 35 HV individuals
demonstrated an accuracy of 80 % and showed an average sensitivity of 70 %, a specificity of 76 %, and a positive
(PPV) and negative predictive value (NPV) of 74 and 75 %, respectively.
Conclusions: These initial findings suggest that the proposed automated EEG analytical approach could be a useful
adjunctive diagnostic approach in clinical practice.
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Background
Depression, a common psychiatric disorder with a life-
time prevalence of ~ 20 % in the general population, is
associated with high rates of disability, impaired psycho-
social functioning and decreased life satisfaction [1].
Early recognition and accurate diagnosis of depression
are essential criteria for optimizing treatment selection
and improving outcomes, thus reducing the economic
and psychosocial burdens resulting from hospitalization,
lost work productivity and suicide [2–4]. Guided by
established classification criteria (DSM-5) [5], the diag-
nosis of psychiatric disorders including depression relies
solely on inferences based on self-reported information
and observed behaviour. Identifying people with estab-
lished depression does not usually present as a clinical
challenge with standard clinical instruments but the
potential for ambiguity, bias and low reliability of a
* Correspondence: Verner.Knott@theroyal.ca
5Institute of Mental Health Research at the Royal Ottawa Mental Health Care
Centre, University of Ottawa, 1145 Carling Avenue, Ottawa, ON K1Z 7 K4,
Canada
Full list of author information is available at the end of the article
© 2015 Mohammadi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mohammadi et al. BMC Medical Informatics and Decision Making  (2015) 15:108 
DOI 10.1186/s12911-015-0227-6
diagnosis of depression based on clinical descriptions
can be compounded by the heterogeneous nature of the
disorder. There are a number of DSM-5 defined depres-
sive disorders (e.g. major depressive disorder [MDD],
dysthymia, depressive disorder not otherwise specified
[NOS]) and, for unipolar MDD, there are symptom based
subtypes (e.g. melancholic, psychotic and atypical de-
pression); symptoms can also vary by gender, age and
even race [6].
Defined as objective biological measures indicating the
state of a normal biologic process, pathogenic process,
or pharmacological response to a therapeutic interven-
tion [7], biomarker use for diagnostics has become stand-
ard in day-to-day practice in medicine (e.g. cardiology,
oncology) but there are no accepted biomarkers for MDD
or other psychiatric disorders. Recent progress has pro-
vided evidence that psychiatric disorders are brain dis-
orders characterized by abnormalities in the structure,
function and neurochemistry in distributed neural net-
works [8]. Neuroimaging, which allows for in vivo access
to these brain circuits, has increased our understanding of
the pathophysiology of these disorders [9, 10] and is a
leading candidate for the development of clinical bio-
markers with potential use for diagnosis, prognosis and
treatment of depression [11–16].
For biomarkers to be diagnostically useful, they need
to be reliable and reproducible, providing sufficiently
high levels of sensitivity and specificity in the detection
and correct classification of distinct disorders [17]. Fur-
thermore, for routine use in clinical practice, they should
be inexpensive, noninvasive and easily accessible [17].
Compared to some other proposed brain imaging bio-
markers derived from functional magnetic resonance
imaging (fMRI), positron emission tomography (PET),
and magnetic resonance spectroscopy (MRS), quantita-
tive measurement of brain electrical signals taken from
the scalp-recorded electroencephalogram (EEG) is a neu-
roimaging technique with clear practical advantages as it
does not involve invasive procedures, is widely available,
easy to administer, well tolerated, and has a relatively low
cost [18]. In addition to its growing potential as a bio-
marker in the therapeutic drug development process
[19, 20] and in predicting antidepressant treatment re-
sponse [21–25], power spectral measures of resting state
EEG oscillatory activity in different frequency bands
(delta [<4 Hz], theta [~4–8 Hz], alpha [~8–12 Hz],
beta [~12–30 Hz) have been shown to distinguish be-
tween depressed patients and healthy controls [26- 28].
However, EEG biomarkers/biosignatures characterizing
brain abnormalities in depressed patients tend to be
limited to group-level comparisons. Although they are
informative in elucidating the neuropathophysiology of
depression, investigations have not systematically exam-
ined whether or not these EEG measurements can be
useful, at the individual level, in diagnosing whether a
given subject is or is not depressed.
Studies focusing on individual-level neuroimaging data
analyses are necessary if this approach is to be clinically
useful [16] but the inherent complexity of the data and
its analyses continues to be an obstacle [10]. Recent
advances in EEG acquisition (high density systems) and
processing has added to this complexity but this growth
has been paralleled by the increased availability of ma-
chine learning methods. Unlike conventional analyses,
machine learning classifiers are designed to deal with
multivariate inputs — treating the EEG measures as pat-
terns rather than considering each measure in isolation
[16, 29, 30]. To date, the limited number of machine
learning studies on resting state EEG in depression have
used varying classification algorithms and have been
found to classify MDD patients and healthy controls with
an overall accuracy ranging between 60–90 % [31–35].
Despite their promise as a supplementary, computer-
aided diagnostic approach, these analytic methods have
not clearly delineated the contributing role of oscillatory
activity in each frequency band and/or brain region to
the machine learning classifiers. Further, they have not
yet examined the role of vigilance states (e.g. eyes open
vs. eyes closed) or recording montages (e.g. unipolar vs.
bipolar EEG recordings). It is also unclear from the
existing machine learning EEG studies if classification
accuracy is different when analyzing data from each fre-
quency band compared to when data from all bands are
analyzed together.
EEG is sensitive to a continuum of states ranging from
stress states, alertness to resting state, and sleep, and
various regions of the brain do not emit the same oscil-
latory activity simultaneously. During the normal state
of wakefulness with eyes open fast frequency (beta) os-
cillations are dominant in central-frontal scalp areas.
During relaxation recorded in an eyes-closed resting
condition, alpha activity in the EEG is dominant in
posterior scalp regions and is markedly diminished
when individuals open their eyes, perhaps reflecting
widespread communication of cortical and thalamo-
cortical interactions to aid information processing of
visual input [36, 37].
Several difference recording reference electrode place-
ments are mentioned in the literature. The choice of
reference may produce topographic distortion in oscilla-
tory signals if a relatively electrically neutral site is not
employed. Referencing to linked mastoids/earlobes and
vertex scalp (Cz) are predominant in the depression
EEG literature and may account for differences across
studies as each technique has its own set of advantages
and disadvantages. Linking reference electrodes from
two earlobes or mastoids reduces the likelihood of ar-
tificially inflating activity in one hemisphere but this
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method may drift away “effective” reference from the
midline plane if electoral resistance at each reference elec-
trode differs [38]. Cz reference is advantageous when it is
located in the middle among active electrodes, however
for closer points it makes poor resolution.
In this study, multi-feature data mining methodologies
were used to classify MDD patients and non-depressed
individuals using EEG data in six frequency bands derived
from 28 scalp sites during both eyes-open and eyes-closed
resting states, and computed with mastoid-based unipolar
(measuring the difference between EEG signals at the
scalp and a neutral non-scalp signal) and Cz-based bipolar
(measuring the EEG difference between pairs of EEG scalp
signals) referenced recordings. The aim was to assess
whether these analytical approaches to EEG may provide
an objective complementary tool to MDD diagnosis.
Methods
Project participants
A sample of 53 adults with a primary diagnosis of MDD
and 43 age matched healthy volunteer (HV) adults partici-
pated in this study. MDD diagnoses were psychiatrist-
confirmed using the Structured Clinical Interview for
DSM (Diagnostic and Statistical Manual of Mental Disor-
ders) IV-TR Diagnoses, Axis I, Patient Version (SCID-IV-
I/P) [39]. The majority of patients had previous MDD
episodes. The Montgomery-Asberg Depression Rating
Scale (MADRS) [40] was used to assess symptom severity.
All patients scored ≥22 (moderate depression) on the
MADRS, and the mean being 30.8 (standard deviation
[S.D.] ± 5.2). Notable study exclusion criteria included:
Bipolar Disorder (BP-I/II or NOS), a history of psychosis,
current (<6 months) drug/alcohol abuse or dependence,
history of seizures or known increased seizure risk, and
any unstable medical condition. Patients presenting with a
significant risk for suicide were excluded, but those
with a secondary diagnosis of some anxiety disorder
were included (N = 33: no anxiety comorbidity; N =
12: sub-threshold anxiety; N = 8; secondary diagnosis of
some form of anxiety). Appropriate drug washout periods
were employed prior to testing for any previously medi-
cated patients; all patients were medication-free at the
time of testing.
HVs were assessed with the non-patient version of the
SCID (SCID-IV-I/NP) and were excluded if they exhib-
ited a psychiatric, neurological (seizures, brain trauma)
or alcohol/drug abuse or dependence history. They were
included only if they scored ≤ 13 on the Beck Depression
Inventory-II (BDI-II) [41] and had no psychiatric history
in first-degree relatives (Family Interview for Genetic
Studies [FIGS]) [42].
This study was approved by the Royal Ottawa Health
Care Group and the University of Ottawa Social Sci-
ences and Humanities Research Ethics Boards. Written
informed consent was obtained from all participants;
each was compensated $30.00 CAN per testing session.
EEG acquisition
Participants were required to abstain from caffeine and
nicotine (minimum of 3 hrs) and alcohol and drugs (be-
ginning at midnight) prior to their test session. Upon
arrival at the laboratory, they were seated in a sound-
and light-attenuated chamber, where EEG recordings
were obtained during 3 min vigilance-controlled eyes-
closed (EC) and 3 min eyes-open (EO) resting conditions
(counter-balanced). EEG was recorded (sampling rate
500 Hz) in reference to activity from electronically linked
mastoids and using a cap system with 28 Ag/AgCl scalp
electrodes (EasyCap, Herrsching-Breitbrunn, Germany)
positioned on the scalp according to the 10–10 system
[43] (Fig. 1). Electrodes placed on the external canthi
and on the supra- and sub-orbital ridges recorded
electrooculographic (EOG) activity, and an electrode
at AFzserved as the ground. Electrode impedances were
maintained at ≤ 5 kΩ and electrical signals were recorded
with amplifier bandpass filter settings of 0.1–80 Hz using
a BrainVision Quickamp amplifier and BrainVision Re-
corder Software (BrainVision, Richardson, TX, USA).
EEG processing
EEG data was processed off-line using BrainVision
Analyzer Software (BrainVision, Richardson, TX, USA).
Signals were referenced with electronically linked mastoid
electrodes (TP9/10) or a scalp vertex (Cz) electrode to yield
two data sets for each of the EC and EO recordings. For
both referenced recordings, signals were filtered (0.1–
30 Hz), ocular corrected [44], and segmented into 2 s
epochs (50 % overlap). Subsequent automatic artifact
rejection was used to exclude epochs with activity exceed-
ing +/− 75 μV. The remaining epochs were visually
inspected for additional artifacts and faulty channels. For
each of EC and EO data sets (linked mastoid and Cz refer-
ences), >100 s artifact-free signals from each of the 28
electrodes (TP9/10 was not used in the analyses) were
subjected to a Fast Fourier Transform (FFT) algorithm
(Hanning window with 5 % cosine taper) for computation
of both absolute and ln-transformed power (μV2) in delta
(1–4 Hz), theta (4–8 Hz), alpha1, (8–10.5 Hz), alpha2
(10.5–13 Hz), alpha total (8–13 Hz) and beta (13–30 Hz)
frequency bands.
Table 1 provides an overview of the raw data vari-
ables collected in 53 depressed patients (MDD) and 43
healthy volunteers (HV) before data pre-processing.
Power values for the four main bands were obtained
for each of the 28 electrodes using two reference mon-
tages (mastoids and Cz) during the eyes-open (EO)
and eyes-closed (EC) conditions. As such, a total of 12
EEG datasets existed.
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Data mining
The Data Mining Methodology was chosen to provide
an outline about the study’s life cycle to tackle the stated
problem and to describe the processes, techniques and
models involved in achieving the study’s goals. The
methodology consists of six phases (Fig. 2), starting with
the initial phase of understanding the project (Introduc-
tion), followed by data understanding (EEG Acquisition/
Processing), data pre-processing, data modeling, evalu-
ation and ending up with the deployment (knowledge
discovery) [45]. The detailed description of each phase
applied in this study is outlined below.
Data pre-processing
The data pre-processing phase includes all the tasks that
are performed to construct and prepare the raw data
into final datasets in order to be fed into the data model-
ing phase [45]. The pre-processing phase consisted of
four main steps which are listed as follows:
Data cleaning The cleaning phase was performed in
Microsoft Excel. Once the datasets were structured and
examined for missing values, a small experiment was
implemented to determine whether absolute or log power
performed better. The results showed that the absolute
power values yielded better accuracy compared with the
log power values.
Data transformation Data transformation was performed
by applying a normalization technique to make all the
data values fall within a small range (0–1) to enable
the efficient performance of the predictive model (clas-
sifier). The employed normalization technique is min-max
normalization, which performs a linear transformation on
the original data by setting the min value to 0 and max
value to 1. “The minimum and maximum values are repre-
sented in the formula (1) with minAand maxAof an attri-
bute A. Min-max normalization maps a value, viof A to vi’
in the range [new_maxA, new_minA]” [46].
Fig. 1 Electrode positions




ðnew maxA − new minAÞ
þ new minA
ð1Þ
Feature selection Genetic Algorithm (GA): This is a
randomized search algorithm used to find an optimal
solution for a problem via the process of natural selec-
tion in data mining [47]. In GA, “chromosomes” are
created randomly to represent the features of the data as
genes. Each gene is assigned with a string of either 0 or
1, where 0 means the feature is not selected in that
particular chromosome whereas 1 means the feature is
selected [48]. For example, Fig. 3 represents a chromo-
some created for EEG data for each band where genes
reflect the 28 electrode sites.
Each chromosome represents a point in the search
space and a number of chromosomes in the space are
called a population. In GA, chromosomes are compared
to each other to assess the goodness of each one in
solving the problem. This is done by using the fitness
function that evaluates and assigns a score for each
Table 1 Data description
References Bands Condition Sites Frequencies Samples
Mastoids Alpha EO Fp1, Fp2, F3, F4, C3, C4, P3, P4, O1, O2, F7, F8, T7, T8, P7,
P8, Fz, Cz, Pz, Oz, Fc1, Fc2, Cp1, Cp2, Fc5, Fc6, Cp5, Cp6
(8–10.5 Hz) HV 43
EC (10.5–13 Hz) MDD 53
Beta EO (13–30 Hz) HV 43
EC MDD 53
Theta EO (4–8 Hz) HV 43
EC MDD 53
Delta EO (1–4 Hz) HV 43
EC MDD 53
Cz Alpha EO Fp1, Fp2, F3, F4, C3, C4, P3, P4, O1, O2, F7, F8, T7, T8, P7,
P8, Fz, Cz, Pz, Oz, Fc1, Fc2, Cp1, Cp2, Fc5, Fc6, Cp5, Cp6
(8–10.5 Hz) HV 43
EC (10.5–13 Hz) MDD 53
Beta EO (8–10.5 Hz) HV 43
EC (13–30 Hz) MDD 53
Theta EO (4–8 Hz) HV 43
EC MDD 53
Delta EO (1–4 Hz) HV 43
EC MDD 43
Fig. 2 Data mining methodology
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chromosome to select the best ones during the selection
phase.
Fitness Function: In the fitness function, each chromo-
some represents features that are selected by GA. Based
on the selected features for each chromosome; a dataset
is generated and is given to the predictive model (classi-
fier) to evaluate the goodness of the chromosome. Be-
fore feeding the classifier with the dataset, the dataset is
mapped using Linear Discrimination Analysis (LDA) and
then divided into training and testing sets. After that,
the training set is fed into the decision tree (classifier) to
build a classification model. Finally, the performance of
the classifier is evaluated using the testing set to deter-
mine how well the classifier performed by computing
the accuracy. To assign the score for each chromosome,
the fitness function is computed using the formula (2).
Fitness ¼ Accuracy − 100 Number of selected features
Total number of feartures
 
ð2Þ
Based on the formula, the chromosomes which contain
fewer features and provide higher detection rate will re-
ceive a higher chance of selection for the next population.
Selection Operator (Tournament Selection): Each
chromosome in the initial population goes through the
same process as described above. Once all the chromo-
somes are assigned scores, they are then compared with
each other in order to select the best ones to reproduce
the next population. In this study, the Binary Tournament
Selection was used [48–51]. In the Binary Tournament
Selection algorithm two chromosomes are first selected
randomly and based on their fitness function, the one that
has a better fitness function is selected and a copy of that
chromosome is sent to the next population. The selection
algorithm repeats the same process until n samples are
selected (n is number of samples in the initial population).
Based on the proposed fitness function, the chromosomes
that have higher fitness value will have a greater chance of
being selected.
Crossover Operator (One-point): The selected popula-
tion during the fitness function needs to be reproduced
to create a new generation of chromosomes for the next
iteration. The crossover method is used to reproduce
new chromosomes for the next population by selecting
two parent chromosomes. From these, two new offspring
chromosomes are produced by applying the crossover.
For example in Fig. 4, parent chromosomes consist of
111010011 and 010111 001, the crossover method ran-
domly chooses loci for exchanging between parents to
create offspring with 111011001 and 010110011 [48–51].
Mutation Operator (Bit Flip): Another method that
is employed to produce a new generation of chromo-
somes is a Mutation, which randomly flips a bit in a
single chromosome. For example, in the chromosome
111010011, the third locus is flipped to 110010011 [48].
Feature mapping Linear Discriminant Analysis (LDA) is
a method used in both feature mapping as well as a
dimensional reduction and classification. LDA was used
as a feature mapping method in order to transfer the
original data into a new space where different classes can
be discriminated linearly by finding a decision region
Fig. 3 Chromosome representation
Fig. 4 Crossover operator—one point
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between the given classes in the newly mapped space that
best maximizes the class separability [50]. Figure 5 shows
a two dimensional dataset before and after applying LDA.
With LDA, the features are mapped into a new feature
space in which they are more linearly discriminant com-
pared with the original feature.
LDA faces difficulties in cases of high dimensional
data, where the LDA matrices are almost always singular
[51]. In our dataset, in some experiments (e.g. Tables 6
& 7); there are more than 110 features while the training
dataset consists of less than 100 samples. This indicates
that it is not feasible to employ LDA directly on the
data. Having observed the low performance of applying
mere LDA on our datasets at the initial stage of the
study, we decided to first employ GA to reduce the data
dimension and then apply LDA to improve the accuracy
of final classifier.
Once the four steps of the preprocessing phase were
completed successfully, the datasets were ready to be classi-
fied by applying the classification model described below.
Data modeling
A Decision Tree (DT) was the selected model for this
study. Specifically, the C4.5 decision tree model was
used. During the training phase, 70 % of the dataset was
used to build a classification model that predicts the
correct label of the testing set (consisting of the rest
(30 %) of the datasets).
Data evaluation
The performance of the DT model was evaluated based
on counting the test records that were correctly and
incorrectly predicted by the DT. The Confusion Matrix
provided information that allowed us to determine how
well the model performed by computing the Accuracy
for correct predictions and Error Rate (ER) for incorrect
predictions, sensitivity, specificity, positive and negative
predicted values [52].
Data mining overview
Before entering the cleansed and normalized data set
into the feature selection phase using the GA, the
datasets were divided into training (70 % of dataset) and
testing (30 % of dataset) datasets, used for building a
predictive model and testing the model’s performance,
respectively. As described in Fig. 6, the input dataset
contains the training set that is fed to the GA in order
to select the best features that discriminate between HVs
and MDD patients, and by applying the fitness function
(explained in Feature selection). The best set of features
was then transformed into a new space to linearly
separate the data based on the classes by applying LDA.
Subsequently, the training set was ready to build the
Decision Tree for the predictive model. The features that
were selected in the training were also selected in the
testing set followed by applying LDA on the testing. Fi-
nally, the mapped testing set was then fed into the
trained decision tree to test if the model was able to pre-
dict MDD patients from HVs and then performance of
the model was measured using the accuracy and the
error rate of the model (described in Data evaluation
Evaluation Phase).
This approach was applied in two sets of analyses. The
first was aimed at analyzing each frequency band indi-
vidually during each of the EO and EC conditions (for
Fig. 5 Linear discriminant analysis
Measurements Formula
Sensitivity : A/(A+ C)*100
Specificity : D/(D+ B)*100
Positive Prediction Value (PPV) : A/(A+ B)*100
Negative Prediction Value (NPV) : D/(D+ C)*100
Positive Likelihood Ratio (LR+) : Sensitivity/(100-Specificity)
Negative Likelihood Ratio (LR-) : (100-Sensitivity)/Specificity
Accuracy : A + D/(A + B + C + D)*100
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each of the mastoid and Cz referenced datasets). Second,
data from all bands were analyzed together during EO
and EC conditions (for each of the mastoid and Cz refer-
enced datasets). Both analyses were performed using
Matlab and IBM SPSS Modeler.
Results
The datasets of the four bands (alpha, beta, delta and
theta) during the EC and EO conditions were analyzed
based on two views to determine the most accurate
approach which might be: 1) Each band was analyzed
individually during each condition EC and EO for each
reference (Mastoid and Cz); and 2) The four bands
(alpha, beta, delta and theta) were grouped together to
be analyzed as one dataset in each condition EC and EO
for Mastoid and Cz references.
Then, the testing dataset was used to validate the
predictive model before and after applying GA and
LDA. After that, the results were evaluated based on
the Sensitivity, Specificity, Positive and Negative Like-
lihood Rates (LR+ and LR-), Positive and Negative
Predictive Values (PPV and NPV), accuracy, and Error
rate for depressed and healthy individuals, see sec-
tions Mastoid reference—bands analyzed individually,
Cz reference—bands analyzed individually, Mastoid
reference—bands analyzed together, and Cz reference—
bands analyzed together for more details of the ana-
lysis. In addition, Section Model evaluation presents the
results of the new obtained datasets, and it is used to
evaluate the model that consists of the whole dataset that
is used through Sections Mastoid reference—bands ana-
lyzed individually, Cz reference—bands analyzed individu-
ally, Mastoid reference—bands analyzed together, and Cz
reference—bands analyzed together.
Mastoid reference—bands analyzed individually
The results of analyzing each band separately during the
EO and EC conditions using a mastoid reference are pre-
sented in Table 2. Apart from the delta band, classification
error rates were relatively high as evidenced by accuracies
ranging from 40–66 %. Low specificities were also noted
in non-delta bands (range: 0–54 %). With more than half
of the classifiers, sensitivity, specificity, Positive Likelihood
Ratio (LR+) and NPV (Negative Predictive Value) rates
increased following GA and LDA application but this was
not necessarily associated with higher accuracy. Delta was
the exceptional individual band classifier when analysed
during EO. Although showing less than chance accuracy
when analyzed with all candidate features, feature reduc-
tion with GA and LDA markedly increased sensitivity,
specificity and accuracy rates > 80 %. These results were
accompanied by increases and decreases in LR+ and LR-,
respectively. As displayed in “Additional file 1: Table S1”
the specific scalp sites contributing to these findings were
distributed over frontal, central and posterior regions of
both hemispheres.
Fig. 6 Overview of the data mining methodology applied in this study
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Cz reference—bands analyzed individually
The results of analyzing each band separately during the
EC and EO conditions using a Cz reference are pre-
sented in Table 3. Although sensitivity, PPV and NPV
rates for some of the classifiers reached 100 %, with the
exception of the alpha (8–10.5 Hz) band, accuracy rates
associated with delta, theta and beta were relatively low
(43–64 % over EO/EC conditions). Similarly modest
accuracy and sensitivity rates (64 %) were observed with
EC and EO alpha band analysis using all candidate
features. However, GA and LDA feature extraction pro-
cesses increased the EC alpha classifier’s sensitivity, PPV,
NPV and accuracy rates to 94, 83, 90 and 86 %, re-
spectively. Scalp recordings contributing to these clas-
sifications were spread diffusely over frontal, central and
parieto-occipital regions (“Additional file 1: Table S2”).
Mastoid reference—bands analyzed together
Table 4 presents the results of analyzing all of the bands
together using either the total (8–13 Hz), or by separat-
ing the low (8–10.5 Hz) or high (10.5–13 Hz) alpha
band data during EO and EC conditions. Overall, accur-
acy rates relying on all candidate features were relatively
low (56–64 %) but the classification accuracy of MDD
patients and HVs significantly increased after feature
selection with GA and LDA, regardless of whether
alpha total (85–86 %), low (88–89 %) or high alpha
band (80–86 %) features were used in the modeling.
Of these, the best results were obtained when reduced
EC low alpha features were used for classification
yielding an accuracy rate approaching 90 %, high sen-
sitivity and specificity rates (89 %), and LR+ (8.09)
and LR- (0.12) values that strongly support this model
for ruling-in and ruling-out depression. While the
“Additional file 1: Tables S3-S5” show that multiple
recording regions contributed to these classifiers, left
and right parietal and occipital recording sites (where
alpha power is typically maximal) did not contribute
to these results.
Cz reference—bands analyzed together
The results of the analysis of all the bands together using
either the total (8–13 Hz), or by separating the low (8–
10.5 Hz) and high (10.5–13 Hz) alpha band data during
EO and EC conditions are presented in Table 5.
Table 2 Results- analysis of the individual bands- mastoid reference
Bands Status # of features Sen. (%) Spec. (%) LR+ LR- PPV (%) NPV (%) Acc. (%) Error depressed Error healthy
Alpha 8–10.5 Hz EC 28 Raw Features 64 Inf Inf Inf 100 0 64 0 10
12 (GA + LDA) 71 55 1.29 0.65 67 50 61 6 5
EO 28 Raw Features 75 63 1.2 0.67 17 90 43 15 1
15 (GA + LDA) 56 80 0.69 2.22 56 20 43 8 8
Alpha 10.5–13 Hz EC 28 Raw Features 67 63 1.06 0.9 33 70 46 12 3
11 (GA + LDA) 67 62 1.08 0.87 56 50 54 8 5
EO 28 Raw Features 77 53 1.44 0.49 56 70 61 8 3
10 (GA + LDA) 82 36 2.26 0.28 78 70 75 4 3
Alpha 8–13 Hz EC 28 Raw Features 64 65 0.98 1.03 39 60 46 11 4
5 (GA + LDA) 73 59 1.24 0.66 44 70 54 10 3
EO 28 Raw Features 77 53 1.44 0.49 56 70 61 8 3
14 (GA + LDA) 100 38 2.67 0 67 100 79 6 0
Beta EC 28 Raw Features 57 71 0.8 1.5 44 40 43 6 10
10 (GA + LDA) 64 64 1 1 50 50 50 9 5
EO 28 Raw Features 59 73 0.81 1.51 56 30 46 7 8
11 (GA + LDA) 67 63 1.07 0.89 44 60 50 10 4
Delta EC 28 Raw Features 67 64 1.04 0.93 11 90 39 16 1
18 (GA + LDA) 56 75 0.75 1.75 50 30 43 9 7
EO 28 Raw Features 58 69 0.85 1.33 39 50 43 11 5
10 (GA + LDA) 88 27 3.24 0.16 83 80 82 2 3
Theta EC 28 Raw Features 64 Inf Inf Inf 100 0 64 0 10
18 (GA + LDA) 79 50 1.57 0.43 61 70 64 7 3
EO 28 Raw Features 69 58 1.18 0.75 61 50 57 7 5
10 (GA + LDA) 75 50 1.5 0.5 67 60 64 6 4
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As shown with mastoid-referenced analyses, analyz-
ing all bands together using total raw features of Cz
referenced EEG yielded low diagnostic accuracy rates
between 31–64 % across EO and EC behavioural
states. Similarly, feature extraction with GA and LDA
elevated accuracies with total alpha (EC/EO: 86,
83 %), low alpha (EC/EO: 90, 83 %), and high alpha
(EC: 88 %) analyses. Further, the more robust classifi-
cations were seen in the analysis conducted with reduced
low alpha features under the EC condition which also
resulted in sensitivity and NPV rates of 100 %, along with
moderate rates of specificity (77 %), LR+ (4.35) and LR-
(0). The scalp regions contributing to the low alpha
classifier were relatively widespread (Additional file 1:
Tables S3-S5”).
Model evaluation
Tables 6 and 7 present the results when newly recorded
(unseen) EEG recordings are analyzed using all the bands
using mastoid or Cz references, and with low, high or total
alpha band features.
Although accuracy was frequently below 60 % for
mastoid and Cz referenced datasets using all candidate
features, classification rates improved to > 70 % using
the reduced features derived with GA and LDA. Accuracy
reached 75–77 % levels with EC and EO Cz referenced
Table 3 Results- analysis of the individual bands- Cz reference
Bands Status # of features Sen. (%) Spec. (%) LR+ LR- PPV (%) NPV (%) Acc. (%) Error depressed Error healthy
Alpha 8–10.5 Hz EC 28 Raw Features 65 50 1.31 0.69 94 10 64 1 9
10 (GA + LDA) 94 25 3.75 0.08 83 90 86 3 1
EO 28 Raw Features 65 50 1.31 0.69 94 10 64 1 9
15 (GA + LDA) 73 54 1.36 0.58 61 60 61 7 4
Alpha 10.5–13 Hz EC 28 Raw Features 67 63 1.07 0.89 44 60 50 10 4
4 (GA + LDA) 64 Inf Inf Inf 100 0 64 0 10
EO 28 Raw Features 64 Inf Inf Inf 100 0 64 0 10
9 (GA + LDA) 74 44 1.66 0.47 78 50 68 4 5
Alpha 8–13 Hz EC 28 Raw Features 64 Inf Inf Inf 100 0 64 0 10
7 (GA + LDA) 100 57 1.77 0 28 100 54 13 0
EO 28 Raw Features 64 Inf Inf Inf 100 0 64 0 10
9 (GA + LDA) 100 52 1.91 0 39 100 61 11 0
Beta 8–10.5 Hz EC 28 Raw Features 58 69 0.85 1.33 39 50 43 10 5
8 (GA + LDA) 62 67 0.92 1.15 44 50 46 11 5
EO 28 Raw Features 58 69 0.85 1.33 39 50 43 10 5
9 (GA + LDA) 75 63 1.2 0.67 17 90 43 15 1
Beta 10.5–13 Hz EC 28 Raw Features 59 73 0.81 1.51 56 30 46 8 7
8 (GA + LDA) 100 44 2.25 0 56 100 71 0 8
EO 28 Raw Features 62 100 0.62 Inf 89 0 57 2 10
11 (GA + LDA) 74 44 1.68 0.46 78 50 68 4 5
Beta 8–13 Hz EC 28 Raw Features 64 0 0.64 Inf 100 0 64 0 10
10 (GA + LDA) 64 0 0.64 Inf 100 0 64 0 10
EO 28 Raw Features 64 0 0.64 Inf 100 0 64 0 10
10 (GA + LDA) 83 70 2.77 0.24 83 70 79 3 2
Delta EC 28 Raw Features 64 0 0.64 Inf 100 0 64 0 10
9 (GA + LDA) 64 0 0.64 Inf 100 0 64 0 10
EO 28 Raw Features 64 0 0.64 Inf 100 0 64 0 10
10 (GA + LDA) 80 61 1.31 0.51 90 22 46 14 1
Theta EC 28 Raw Features 64 0 0.64 Inf 100 0 64 0 10
9 (GA + LDA) 100 57 1.77 0 28 100 54 13 0
EO 28 Raw Features 77 53 1.44 0.49 56 70 61 8 3
12 (GA + LDA) 64 0 0.64 Inf 100 0 64 0 10
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EEG, but the maximal 80 % accuracy was evidenced
with EO low alpha analysis, which also yielded sensi-
tivity and specificity rates of 77 % and 80 %, respect-
ively, together with relatively high PPV (78 %) and
NPV (80 %) values.
As indicated in Tables 6 and 7, the model shows an
acceptable performance on the newly recorded data. The
accuracy of the model fluctuates between 70 % and
80 %. For example, based on the Cz reference, EC data-
set with all bands (Table 7), the accuracy of the model
on 106 raw features is about 60 %, while by applying the
proposed method, the accuracy reaches 72.7 % which is
a noticeable improvement.
Discussion
The heterogeneity of symptom profiles and severity
among patients with MDD is a major challenge for diag-
nostic classification. Further, given the reliability prob-
lems associated with subjective assessments of clinical
phenomena there is an increasing effort to identify more
Table 4 Mastoid reference results (For around 28 records)
Status # of features Sen. (%) Spec. (%) LR+ LR- PPV (%) NPV (%) Acc. (%) Error depressed Error healthy
Alpha (8–10.5 Hz), Beta, Delta & Theta
EC 112 Raw Features 69 43 1.21 0.72 53 60 56 8 4
60 GA + LDA 89 89 8.09 0.12 94 80 89 1 2
EO 112 Raw Features 68 50 1.36 0.64 83 30 64 3 7
58 GA + LDA 94 75 3.76 0.08 83 90 88 3 1
Alpha (10.5–13 Hz), Beta, Delta & Theta
EC 112 Raw Features 73 78 3.32 0.35 80 70 75 2 3
46 GA + LDA 77 100 Inf 0.23 100 70 86 0 3
EO 112 Raw Features 62 71 2.14 0.54 80 50 65 2 5
42 GA + LDA 80 80 4 0.24 80 80 80 2 2
Alpha (8–13 Hz), Beta, Delta & Theta
EC 112 Raw Features 62 33 0.93 1.15 76 20 56 4 8
60 GA + LDA 88 80 4.4 0.15 88 80 85 2 2
EO 112 Raw Features 67 40 1.12 0.83 67 40 57 6 6
58 GA + LDA 94 75 3.76 0.08 83 90 86 3 1
Table 5 Cz reference results
Status # of features Sen. (%) Spec. (%) LR+ LR- PPV (%) NPV (%) Acc. (%) Error depressed Error healthy
Alpha (8–10.5 Hz), Beta (8–10.5 Hz), Delta & Theta
EC 109 Raw Features 55 28 0.76 1.61 32 50 38 13 5
59 GA + LDA 100 77 4.35 0 84 100 90 3 0
EO 109 Raw Features 55 72 1.96 0.63 32 50 34 13 5
55 GA + LDA 85 78 3.86 0.19 89 70 83 2 3
Alpha (10.5–13 Hz), Beta (10.5–13 Hz), Delta & Theta
EC 109 Raw Features 88 53 1.87 0.23 47 90 64 8 1
50 GA + LDA 100 77 4.35 0 80 100 88 3 0
EO 109 Raw Features 88 53 1.87 0.23 47 90 64 8 1
57 GA + LDA 90 60 2.25 0.16 60 90 72 6 1
Alpha (8–13 Hz), Beta (8–13 Hz), Delta & Theta
EC 109 Raw Features 47 14 0.55 3.79 37 20 31 12 8
59 GA + LDA 94 75 3.76 0.08 84 90 86 3 1
EO 109 Raw Features 75 38 1.21 0.66 32 80 48 13 2
64 GA + LDA 100 66 2.94 0 74 100 83 5 0
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brain-based, objective and reliable classifiers for various
psychiatric disorders, including depression. In this paper,
classification approaches were performed on EEG signal
features (power density in different frequency bands)
derived from multiple scalp recording sites, during two
states (EO/EC) and analyzed using two reference mon-
tages. In Experiment 1, individual bands resulted in
relatively high classification errors, regardless of whether
or not the complexity and redundancy of signal features
was reduced by the genetic algorithm. Exceptions were
observed with EO mastoid-referenced delta and EC
Cz-referenced total alpha, with the reduced extracted
features of each band exhibiting > 80 % accuracy, sen-
sitivity and PPVs. These latter findings are generally
supportive of previous group-level comparison studies
showing activity of alpha, and to a lesser extent delta
oscillations to distinguish depressed and healthy vol-
unteer samples [26].
When analyzing each band separately, classification
was similarly less than optimal in Experiment 2 when
bands were analyzed together and with the total set of
candidate features, but was markedly increased following
feature reduction. Regardless of the type of reference
(mastoid vs. Cz) or vigilance state (EC vs. EO), most
Table 6 Mastoid reference results on the new unseen 44 records
Status # of features Sen. (%) Spec. (%) LR+ LR- PPV (%) NPV (%) Acc. (%) Error depressed Error healthy
Alpha (8–10.5 Hz), Beta, Delta & Theta
EC 112 Raw Features 56 51 1.1 0.8 56 51 52 4 17
60 GA + LDA 78 74 3.02 0.2 78 74 75 2 9
EO 112 Raw Features 22 71 0.7 1.08 22 71 61 7 10
58 GA + LDA 78 80 3.8 0.2 78 80 80 2 7
Alpha (10.5–13 Hz), Beta, Delta & Theta
EC 112 Raw Features 56 60 1.3 0.7 56 60 59 4 14
46 GA + LDA 78 69 2.4 0.3 78 69 70 2 11
EO 112 Raw Features 44 66 1.2 0.8 44 66 61 5 12
42 GA + LDA 67 74 2.5 0.4 67 74 73 3 9
Alpha (8–13 Hz), Beta, Delta & Theta
EC 112 Raw Features 33 57 0.7 1.1 33 57 52 6 15
60 GA + LDA 78 77 3.4 0.2 78 77 77 2 8
EO 112 Raw Features 56 43 0.9 1.03 56 43 45 4 20
58 GA + LDA 67 74 2.5 0.4 67 74 73 3 9
Table 7 Cz Reference Results on the new unseen 44 records
Status # of features Sen. (%) Spec. (%) LR+ LR- PPV (%) NPV (%) Acc. (%) Error depressed Error healthy
Alpha (8–10.5 Hz), Beta (8–10.5 Hz), Delta & Theta
EC 109 Raw Features 56 43 0.9 1.03 56 43 45 4 20
59 GA + LDA 67 80 3.3 0.4 67 80 77 3 7
EO 109 Raw Features 11 54 0.2 1.6 11 54 45 8 16
55 GA + LDA 67 77 2.9 0.4 67 77 75 3 8
Alpha (10.5–13 Hz), Beta (10.5–13 Hz), Delta & Theta
EC 109 Raw Features 33 66 0.9 1.01 33 66 59 6 12
50 GA + LDA 78 77 3.4 0.2 78 77 77 2 8
EO 109 Raw Features 56 60 1.3 0.7 56 60 59 4 14
57 GA + LDA 67 74 2.5 0.4 67 74 73 3 9
Alpha (8–13 Hz), Beta (8–13 Hz), Delta & Theta
EC 109 Raw Features 33 57 0.7 1.1 33 57 52 6 15
59 GA + LDA 56 80 2.7 0.5 56 80 75 4 7
EO 109 Raw Features 22 54 0.4 1.4 22 54 48 7 16
64 GA + LDA 67 80 3.3 0.4 67 80 77 3 7
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models exhibited low classification errors, with high
accuracy and sensitivity values. The electrode sites con-
tributing to these classifiers and the above-mentioned
single band delta and alpha classifiers were widely dis-
tributed across frontal, temporal and posterior regions in
both hemispheres. These data are consistent with func-
tional neuroimaging studies that tend to characterize
depression as a dysfunction in a network(s) of discrete,
but functionally integrated, cortico-limbic pathways [53],
which can be assessed by brain-based algorithms for
diagnosis and optimized treatment [54, 56].
In summary, the most accurate decision tree models
(accuracies > 80 %) were evaluated with unseen data from
44 participants, including 35 HVs and 9 MDD patients.
Correct diagnosis rates of the models were found to be
quite accurate. These results generally support the notion
that data mining techniques, and especially those involv-
ing feature extraction, may yield promising classifiers
for the EEG signal processing applications, specifically
in cases of MDD and control subjects classification.
Improved classification accuracies may possibly be achieved
with the addition of other candidate features besides
EEG power including EEG coherence and cordance
measures, which have been reported to distinguish de-
pressed patients from healthy volunteers, and the EEG
antidepressant response (ATR) index, which has predicted
treatment response in depressed patients [26, 27].
Conclusions
In this study we demonstrated that data mining applied
to EEG signals may be a useful tool in discriminating
between depressed and healthy individuals. Given the
questionable reliability of diagnoses based on clinical
symptoms, this quantitative methodology may be a useful
adjunctive clinical decision support for identifying depres-
sion and it supports independent studies confirming the
potential clinical utility of computer-aided diagnosis of
depression using EEG signals [55].
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